Combining Tyroserleutide with Doxorubicin for Cancer Treatment
Author Information
Author(s): Zhu Zhi-feng, Chen Li-juan, Lu Rong, Jia Jing, Liang Yu, Xu Qiong, Zhou Chun-lei, Wang Li, Wang Song, Yao Zhi
Primary Institution: Tianjin Medical University
Hypothesis
Does the combination of tripeptide tyroserleutide (YSL) and doxorubicin enhance anti-tumor effects while reducing side effects in mice with liver cancer?
Conclusion
The combination of YSL plus doxorubicin enhances the anti-tumor effect and reduces the side effects associated with doxorubicin chemotherapy.
Supporting Evidence
- YSL plus high-dose doxorubicin prolonged survival time compared to doxorubicin alone.
- YSL reduced side effects like weight loss and organ damage from doxorubicin.
- The combination therapy showed a higher tumor inhibition rate than doxorubicin alone.
Takeaway
This study shows that a special peptide can help a common cancer drug work better and hurt the body less.
Methodology
Nude mice with human liver cancer were treated with different doses of doxorubicin alone or in combination with YSL, and tumor growth and side effects were measured.
Limitations
The study was conducted on mice, which may not fully represent human responses.
Participant Demographics
Healthy female BALB/c (nu/nu) mice, 4–5 weeks old.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website